MedTrace Logo

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

NCT05734495 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-05-11

No results posted yet for this study

Summary

This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM).

The names of the study drugs involved in this study are:

* Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor)
* Venetoclax (a BCL2 inhibitor)

Conditions

Interventions

DRUG

Pirtobrutinib

Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor, tablet taken orally.

DRUG

Venetoclax

Small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor, tablet taken orally.

Sponsors & Collaborators

Principal Investigators

  • Jorge Castillo, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-02
Primary Completion
2029-01-25
Completion
2033-01-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05734495 on ClinicalTrials.gov